We boldly develop novel therapeutics utilizing cellular gene editing and complex cytokines We boldly develop novel therapeutics utilizing cellular gene editing and complex cytokines OUR FOCUS
Brooklyn ImmunoTherapeutics (BTX) is committed to creating a world in which patients and families with high unmet medical needs have access to effective treatments. To achieve this, we are focused on three primary approaches:
- iPSC-derived, iMSC-based therapeutics
- In vivo gene editing products
- IRX-2, a human cell-derived (hd) IL-2 therapeutic
LATEST NEWS
Brooklyn ImmunoTherapeutics to Move Stock Exchange Listing to Nasdaq
[ READ MORE ]
Brooklyn ImmunoTherapeutics Appoints Roger Sidhu, M.D. as Chief Medical Officer
[ READ MORE ]
Brooklyn ImmunoTherapeutics Provides Highlights of Shareholder Update Call from September 20, 2021
[ READ MORE ]
Brooklyn ImmunoTherapeutics to Conduct Shareholder Update Conference Call on Monday, September 20, 2021, at 4:30 PM ET
[ READ MORE ]
LATEST PRESENTATION